Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estimated Diabetes In Japan Grows To One Per Every 5.6 Adults

This article was originally published in PharmAsia News

Executive Summary

According to a National Health and Diet Survey of 2006 conducted by Japan's Ministry of Heath, Labor and Welfare, released on April 30, the total number of diabetes patients and candidates is estimated to be 18.7 million, an increase of 15.4 percent or 2.5 million since 2002. MHLW sites a rapidly aging population, lack of exercise and high calorie diets as reasons. The estimate is based on a survey conducted in 3,600 families and utilizing blood samples of 4,296 adults. (Click here for more - Japanese language

You may also be interested in...



AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan

TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel